Trials / Conditions / PALB2 Gene Mutation

PALB2 Gene Mutation

13 registered clinical trials studyying PALB2 Gene Mutation — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alter NCT06392841	Qian Qin	Phase 2
Recruiting	Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer NCT06783140	University Health Network, Toronto	Phase 2 / Phase 3
Active Not Recruiting	Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion NCT06033092	European Institute of Oncology	Phase 2
Recruiting	Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors NCT06177171	Pamela Munster	Phase 1
Recruiting	Combination Therapy in Cancers With Mutations in DNA Repair Genes NCT05694715	University of California, San Francisco	Phase 1
Recruiting	An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk a NCT05420064	Memorial Sloan Kettering Cancer Center	N/A
Active Not Recruiting	The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics NCT05692596	H. Lee Moffitt Cancer Center and Research Institute	—
Recruiting	SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells NCT04150042	General Oncology, Inc.	Phase 1
Active Not Recruiting	Olaparib In Metastatic Breast Cancer NCT03344965	Beth Israel Deaconess Medical Center	Phase 2
Suspended	Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) NCT02993068	M.D. Anderson Cancer Center	N/A
Completed	Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer NCT03377556	SWOG Cancer Research Network	Phase 2
Recruiting	The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation. NCT05097274	Institute of Cancer Research, United Kingdom	—
Active Not Recruiting	Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations i NCT02286687	M.D. Anderson Cancer Center	Phase 2